Alefacept

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)


Volume 15, 3 Issues, 2016


Download PDF Flyer




Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Claudiu T. Supuran
Neurofarba Department
University of Florence
Florence
Italy


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Alefacept



Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 6(3): 211-216.

Author(s): Mustafa Turhan Sahin.

Affiliation: Department of Dermatology, Medical Faculty, Celal Bayar University, Manisa, Turkey.

Abstract

Alefacept is a fully human fusion protein, being the first biologic agent approved for the treatment of chronic, moderate to severe plaque-type psoriasis. Its dual mechanism of action involves inhibition of T-cell activation and selective reduction of memory T cells. It has a slow onset of action, peaking approximately 18 weeks after the first injection. However, it is associated with long remissions without the need for maintenance therapy in psoriatic patients and its efficacy improves with subsequent courses with a high safety profile. The mechanism of action, the results of the clinical trials, its efficacy, pharmacodynamic effects on circulating lymphocytes, and safety and tolerability of alefacept are summarized in this review. Current treatment guidelines are also presented.

Keywords:

Psoriasis area severity index, lymphocyte-function associated antigen-3, memory T cells, Alopecia areata, Quality of life.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 6
Issue Number: 3
First Page: 211
Last Page: 216
Page Count: 6
DOI: 10.2174/187152307781368229
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science